Abstract: Computational systems and methods are described for identifying new type-ll bacteriocins using a systemic consensus formula and other related criteria. Newly identified type-ll bacteriocin peptides are tested experimentally and show potent microbicidal activities. Further provided are the sequences of Newly identified type-ll bacteriocin peptides, and a method of treating an infection in a patient in need thereof, comprising administering to the patient an effective amount of a peptide comprising an amino acid sequence disclosed.
Type:
Grant
Filed:
May 10, 2018
Date of Patent:
September 21, 2021
Assignee:
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
Abstract: Provided are processes and materials for solving biological or structural information about proteins or other organic molecules. The processes capitalize on a rigid multimeric nanocage formed from self-assembling substructure proteins. The processes and materials allow for recognition and tight, optionally covalent, bonding of any protein molecule with a tag complementary to a capture sequence on the nanocage. The processes and materials may be used to obtain biological or structural information by cryo-electron microscopy and overcome prior limitations of target protein size or salt concentration.
Abstract: The invention generally relates to pharmaceuticals and/or nutraceuticals. More particularly, the invention provides compositions of collagen-based peptides and specific digestive tract microbes useful for supporting or promoting joint, skin and/or bone health, and methods of preparation and use thereof. The invention further provides for the use of compositions of collagen-based peptides as a prebiotic for modulating the gut microbiome.
Type:
Grant
Filed:
March 1, 2018
Date of Patent:
September 7, 2021
Assignees:
UNIVERSITY OF ROCHESTER
Inventors:
Michael Zuscik, Janne Prawitt, Eric Schott, Robert Mooney, Christopher Farnsworth
Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
Type:
Grant
Filed:
October 4, 2018
Date of Patent:
September 7, 2021
Assignee:
Zealand Pharma A/S
Inventors:
Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
Abstract: The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.
Type:
Grant
Filed:
July 18, 2018
Date of Patent:
August 17, 2021
Assignees:
TOKUSHIMA UNIVERSITY, ONCOTHERAPY SCIENCE, INC.
Abstract: The present invention provides an agent for promoting skeletal muscle injury repair which agent comprises at least one peptide selected from the following (1) to (4): (1) a peptide consisting of the amino acid sequence of SEQ ID NO: 1, (2) a peptide consisting of the amino acid sequence of SEQ ID NO: 2, (3) a peptide consisting of the amino acid sequence of SEQ ID NO: 3, and (4) a peptide which is a human osteopontin fragment and has the amino acid sequence of SEQ ID NO: 1, 2, or 3 at the C-terminus, or a salt thereof as an active ingredient.
Abstract: The present invention relates to a cosmetic or pharmaceutical composition containing a cell culture medium and, as an active ingredient, albumin, hyaluronic acid or collagen. The composition according to the present invention can be useful as a cosmetic or pharmaceutical composition for alleviating, preventing or treating skin wounds, skin diseases or skin conditions, by increasing the recovery capability of cells.
Abstract: The present invention relates to a method for preventing and treating tissue and organ fibrosis, comprising administering an effective amount of plasminogen to a subject.
Abstract: The present invention provides certain lipo-glycopeptide cleavable derivatives and methods for using the same for the treatment of bacterial infections, for example, pulmonary bacterial infections. The LGPC derivatives include a cleavable moiety that in certain embodiments, is designed to allow for cellular uptake and/or a more rapid clearance of the glycopeptide metabolite (i.e., the cleaved glycopeptide) from the site of administration (e.g., the lung) as compared to the uncleaved LGPC.
Type:
Grant
Filed:
May 22, 2018
Date of Patent:
July 27, 2021
Assignee:
Insmed Incorporated
Inventors:
Ryan Heckler, Donna Konicek, Adam Plaunt, Vladimir Malinin, Walter Perkins
Abstract: A cyclic peptide is represented by Formula (I), RN—Xg—[Xi—Xa—Xm—X1—X2—X3—Xn—Xb—Xj]k—Xh—RC??(I) in Formula (I), RN represents an N-terminal group; RC represents a C-terminal group; X1 represents an L-leucine residue, an L-isoleucine residue, an L-methionine residue, an L-lysine residue, or an L-arginine residue; X2 represents an L-valine residue or an L-isoleucine residue; X3 represents an L-tryptophan residue or an L-phenylalanine residue; one of Xa and Xb represents an amino acid residue derived from an amino acid having an azide group on a side chain and the other represents an amino acid residue derived from an amino acid having an alkynyl group on a side chain, and Xg, Xh, Xi, Xj, Xm, and Xn each represent g consecutive X's, h consecutive X's, i consecutive X's, j consecutive X's, m consecutive X's, and n consecutive X's; X represents an amino acid residue.
Abstract: This disclosure provides compositions and methods for improving erythrocyte dysfunction or treating a hemoglobinopathy or a thalassemia (e.g., sickle cell disease or ?-thalassemia).
Type:
Grant
Filed:
June 19, 2019
Date of Patent:
July 13, 2021
Assignee:
AXCELLA HEALTH INC.
Inventors:
Sean Carroll, Matthew Russell, Raffi Afeyan
Abstract: A bioactive collagen biomaterial according to the invention that is biocompatible with cells and tissues and distinguished by containing certain cryptic and non-cryptic peptide constituents to stimulate cellular responses and further made to incorporate a variety of agents to provide a desired characteristic, such as antimicrobial properties. The bioactive collagen biomaterial can be provided as a variety of configurations and as various matrices and devices for use in medical applications such as in biotechnology, basic research, tissue engineering and in wound repair as a wound dressing or cell/tissue scaffold.
Abstract: The present invention relates to a two-part linker comprising a peptide tag (peptide) and a polypeptide (protein) that is capable of spontaneously forming an isopeptide bond, particularly wherein: a) said peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1, wherein: (i) X at position 1 is arginine or no amino acid; (ii) X at position 2 is glycine or no amino acid; (iii) X at position 5 is histidine or threonine; (iv) X at position 11 is alanine, glycine or valine; and (v) X at position 14 is arginine or lysine, wherein when X at position 1 is no amino acid, X at position 2 is no amino acid; and b) said polypeptide comprises: i) an amino acid sequence as set forth in SEQ ID NO: 2; ii) a portion of (i) comprising an amino acid sequence as set forth in SEQ ID NO: 101; iii) an amino acid sequence with at least 80% sequence identity to a sequence as set forth in SEQ ID NO: 2, wherein said amino acid sequence comprises a lysine at position 34, a glutamic acid at position 80 and one or more of the
Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
Abstract: Systems and methods for acquiring, preserving, and administering delipidated plasma. Extracted delipidated plasma, comprising pre-beta HDL, is obtained and are spot tested to establish baseline amounts or concentrations of pre-beta HDL. The batches are subjected to preservation, stored, and then prepared again for use at some later date. A portion of the batch may be tested again to determine if the pre-beta HDL in the delipidated plasma has degraded or is no longer effective.
Type:
Grant
Filed:
September 15, 2020
Date of Patent:
June 15, 2021
Assignee:
HDL Therapeutics, Inc.
Inventors:
Hollis Bryan Brewer, Jr., Michael M. Matin
Abstract: Disclosed herein are hydrolyzed collagen compositions. The compositions are inexpensive to make and can be produced without the use of proteolytic enzymes, decolorizing agents, antibacterial and antifungal agents, and the like. Further, the compositions are substantially free of odors and are white to light yellow in color and are suitable to be used as dietary supplements. Also disclosed are methods for producing the compositions.
Type:
Grant
Filed:
March 18, 2019
Date of Patent:
June 8, 2021
Assignee:
AVICENNA NUTRACEUTICAL, LLC
Inventors:
Ali Elnajjar, Ali Mourad, Mark Ernst Brandt, Christopher Lippelt
Abstract: The invention disclosed herein relates to peptide inhibitors for transthyretin (TTR) aggregation and methods of inhibiting TTR aggregation, cytotoxicity, and/or TTR amyloidosis. Illustrative embodiments of the invention include a composition of matter comprising at least one peptide designed to inhibit the aggregation of TTR, with this peptide typically being coupled to a heterologous amino acid tag. A pharmaceutically acceptable carrier selected to be compatible with the inhibitory peptide may also be included. A method for blocking or inhibiting the aggregation of transthyretin TTR is also provided. The method comprises combining TTR with an effective amount of an inhibitory peptide or pharmaceutical composition, so that TTR aggregation and/or cytotoxicity is blocked or inhibited.
Type:
Grant
Filed:
June 29, 2017
Date of Patent:
June 8, 2021
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
David S. Eisenberg, Lorena Saelices Gomez
Abstract: The disclosed compositions and methods relate to the increasing muscle mass, preventing muscle atrophy, promoting muscle growth, as well as treatment of various other conditions and diseases. In certain aspects, the disclosed compositions are comprised dileucine and leucine and pharmaceutically acceptable salts thereof. In certain aspects, disclosed compositions are administered to subjects in need thereof to increase muscle mass, prevent muscle atrophy, and/or promote muscle growth.
Type:
Grant
Filed:
April 18, 2019
Date of Patent:
June 8, 2021
Assignee:
Ingenious Ingredients, LP
Inventors:
Martin Purpura, Ralf Jaeger, Shawn Wells, Kylin Lao, Anton Fliri
Abstract: The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
Type:
Grant
Filed:
August 27, 2018
Date of Patent:
May 18, 2021
Assignee:
Zealand Pharma A/S
Inventors:
Anne Pernille Tofteng Shelton, Pia Nørregaard, Jacob Ulrik Fog, Carsten Boye Knudsen
Abstract: The present invention relates to the field of (bio-)medicine, and more particularly to the treatment of copper-related diseases. Novel means and methods for depleting (excess) copper from organs and/or the circulation are provided. Agents with a high copper binding affinity and stabilized forms thereof are provided, as well as a novel treatment regimen. The means and methods of the present invention are particularly useful for treatment of Wilson Disease, but also for treatment of other conditions.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
May 11, 2021
Assignees:
HELMHOLTZ ZENTRUM MÜNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH), IOWA STATE UNIVERSITY RESEARCH FOUNDATION, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors:
Hans Zischka, Josef Lichtmannegger, Alan Angelo Dispirito, Jeremy David Semrau